One-Year Comparative Effectiveness of Upadacitinib vs Tofacitinib for Ulcerative Colitis: A Multicenter Cohort Study.
Am J Gastroenterol
; 2024 Apr 01.
Article
em En
| MEDLINE
| ID: mdl-38470031
ABSTRACT
INTRODUCTION:
The comparative effectiveness of upadacitinib and tofacitinib for ulcerative colitis (UC) is poorly understood.METHODS:
In this retrospective cohort study, we compared steroid-free clinical remission (SFCR) and endoscopic response/remission at 52 weeks among adults initiating upadacitinib or tofacitinib for UC.RESULTS:
A total of 155 patients initiated upadacitinib (n = 81; 30% prior tofacitinib exposure) or tofacitinib (n = 74; 0% prior upadacitinib exposure). After inverse probability of treatment-weighted logistic regression, upadacitinib was associated with significantly higher odds of SFCR (odds ratio 3.01, 95% confidence interval 1.39-6.55) vs tofacitinib. There were no differences for endoscopic response/remission.DISCUSSION:
Upadacitinib was more effective at achieving SFCR in UC at 52 weeks vs tofacitinib.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article